Status:
TERMINATED
Glycine Supplement for Severe COVID-19
Lead Sponsor:
Instituto Nacional de Enfermedades Respiratorias
Conditions:
COVID-19
SARS-CoV Infection
Eligibility:
All Genders
Phase:
NA
Brief Summary
This study will explore whether a daily supplement of glycine, a substance that has antiinflammatory, cytoprotective, and endothelium-protecting effects, can improve mortality, as well as clinical and...
Detailed Description
Patients with severe forms of COVID-19 often develop acute respiratory distress syndrome (ARDS) associated with high levels of proinflammatory cytokines and damage of lungs and other organs. A special...
Eligibility Criteria
Inclusion
- Any age.
- Any sex.
- With COVID-19 confirmed (or awaiting confirmation) by PCR.
- With a clinical decision of initiation of mechanical ventilation or with \<48 h under mechanical ventilation.
- Informed consent signed by the participant's responsible.
Exclusion
- Pregnant women.
- Already participating in another research protocol.
- Elimination Criteria:
- Voluntary hospital discharge or referenced to another institution.
Key Trial Info
Start Date :
June 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 14 2021
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT04443673
Start Date
June 15 2020
End Date
June 14 2021
Last Update
August 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Enfermedades Respiratorias
Mexico City, Mexico, 14080